BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Analyst Ratings
USA - NASDAQ:BCRX - US09058V1035 - Common Stock
7.145 USD
+0.38 (+5.7%)
ChartMill assigns a Buy % Consensus number of 84% to BCRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 21.51. This target is 201.09% above the current price.
BCRX was analyzed by 17 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about BCRX.
In the previous month the buy percentage consensus was at a similar level.
BCRX was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-05 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-04 | Needham | Maintains | Buy -> Buy |
| 2025-11-04 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-10-15 | TD Cowen | Reiterate | Buy |
| 2025-10-15 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-10-15 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-10-15 | Needham | Maintains | Buy -> Buy |
| 2025-08-04 | Needham | Maintains | Buy -> Buy |
| 2025-07-01 | B of A Securities | Maintains | Buy -> Buy |
| 2025-06-30 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-06-30 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-06-27 | Needham | Reiterate | Buy -> Buy |
| 2025-06-25 | Needham | Reiterate | Buy -> Buy |
| 2025-05-07 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-06 | Needham | Maintains | Buy -> Buy |
| 2025-05-06 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-05-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-29 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-04-11 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-03-03 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-25 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-25 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-02-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-31 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-01-13 | Needham | Maintains | Buy -> Buy |
| 2025-01-13 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-11-05 | Needham | Reiterate | Buy -> Buy |
| 2024-11-05 | RBC Capital | Reiterate | Outperform -> Outperform |
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
What do analysts expect the price target to be for BIOCRYST PHARMACEUTICALS INC (BCRX)?
17 analysts have analysed BCRX and the average price target is 21.51 USD. This implies a price increase of 201.09% is expected in the next year compared to the current price of 7.145.
What is the consensus rating for BIOCRYST PHARMACEUTICALS INC (BCRX) stock?
The consensus rating for BIOCRYST PHARMACEUTICALS INC (BCRX) is 83.5294 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for BIOCRYST PHARMACEUTICALS INC stock?
The number of analysts covering BIOCRYST PHARMACEUTICALS INC (BCRX) is 17.